Understanding heterogeneity in supplementation effects of selenium in men: A study of stratification variables and human genetics in a prospective sample from New Zealand

Current Pharmacogenomics and Personalized Medicine

Volumn 10, Issue 3, 2012, Pages 204-216

  Ferguson, Lynnette R ^a,b,c   Karunasinghe, Nishi ^a   Zhu, Shuotun ^a   Han, Dug Yeo ^b   Triggs, Christopher M ^d   Wang, Alice H ^a   Masters, Jonathan G ^e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Nutrigenomics New Zealand   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Benefit variability by age; BMI; Health status; Nutrigenetics; Personalising chemoprevention; Se supplementation; Seleno genotypes

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE PEROXIDASE; PEROXIDE; SELENIUM; THIOREDOXIN REDUCTASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BODY MASS; DEMOGRAPHY; DNA DAMAGE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; GENE; GENETIC HETEROGENEITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GPX1 GENE; GPX4 GENE; GROUPS BY AGE; HEALTH STATUS; HEREDITY; HUMAN; LIFESTYLE; MALE; MULTICENTER STUDY; NEW ZEALAND; NORMAL HUMAN; PERSONALIZED MEDICINE; PROSPECTIVE STUDY; QUESTIONNAIRE; SEL15 GENE; SELS GENE; SEPP1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SUPPLEMENTATION;

EID: 84867021651     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569212802509997     Document Type: Article

References (91)

1. Chen J. An original discovery: Selenium deficiency and Keshan disease (an endemic heart disease). Asia Pac J Clin Nutr 2012; 2(3): 320-6.
2. Fairweather-Tait SJ, Bao Y, Broadley MR, et al. Selenium in human health and disease. Antioxid Redox Signal 2011; 14(7): 1337-83.
3. Rayman MP. Selenium and human health. Lancet 2012; 379(9822): 1256-68.
4. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial. JAMA 1996; 276(24): 1957-63.
5. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 1998; 81(5): 730-34.
6. Karunasinghe N, Han DY, Zhu S, et al. Serum selenium and single nucleotide polymorphisms in genes for selenoproteins: Relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr 2012; 7(2): 179-90.
7. Karunasinghe N, Ryan J, Tuckey J, et al. DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(3): 391-7.
8. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
9. El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 2009; 61(3): 285-6.
10. Marshall JR, Ip C, Romano K, et al. Methyl selenocysteine: Singledose pharmacokinetics in men. Cancer Prev Res (Phila) 2011; 4(11): 1938-44.
11. Rayman MP. Selenoproteins and human health: Insights from epidemiological data. Biochim Biophys Acta 2009; 1790(11): 1533-40.
12. Rayman MP, Combs GF Jr, Waters DJ. Selenium and vitamin E supplementation for cancer prevention. JAMA 2009; 301(18): 1876-82.
13. Schrauzer GN. Re: Lessons from the selenium and vitamin E cancer prevention trial (SELECT). Crit Rev Biotechnol 2009; 29(2): 81.
14. Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis 2010; 4(3): 165-83.
15. Akbaraly TN, Arnaud J, Rayman MP, et al. Plasma selenium and risk of dysglycemia in an elderly french population: Results from the Prospective Epidemiology of Vascular Ageing Study. Nutr Metab (Lond) 2010; 721.
16. Kljai K, Runje R. Selenium and glycogen levels in diabetic patients. Biol Trace Elem Res 2001; 83(3): 223-9.
17. Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann Intern Med 2007; 147: 217-23.
18. Bleys J, Navas-Acien A, Guallar E. Serum selenium and diabetes in U.S. Adults. Diabetes Care 2007; 30(4): 829-34.
19. Mokhber N, Namjoo M, Tara F, et al. Effect of supplementation with selenium on postpartum depression: A randomized doubleblind placebo-controlled trial. J Matern Fetal Neonatal Med 2011; 24(1): 104-8.
20. Pasco JA, Jacka FN, Williams LJ, et al. Dietary selenium and major depression: A nested case-control study. Complement Ther Med 2012; 20(3): 119-23.
21. Muecke R, Schomburg L, Buentzel J, et al. Selenium or no selenium-that is the question in tumor patients: A new controversy. Integr Cancer Ther 2010; 9(2): 136-41.
22. Maiorino M, Aumann KD, Brigelius-Flohe R, et al. Probing the presumed catalytic triad of selenium-containing peroxidases by mutational analysis of phospholipid hydroperoxide glutathione peroxidase (PHGPX). Biol Chem Hoppe Seyler 1995; 376(11): 651-60.
23. Rocher C, Lalanne JL, Chaudiere J. Purification and properties of a recombinant sulfur analog of murine selenium-glutathione peroxidase. Eur J Biochem 1992; 205(3): 955-60.
24. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 2006; 16(6): 452-65.
25. Reeves MA, Hoffmann PR. The human selenoproteome: Recent insights into functions and regulation. Cell Mol Life Sci 2009; 66(15): 2457-78.
26. Burk RF, Hill KE. Selenoprotein P- expression, functions, and roles in mammals. Biochim Biophys Acta 2009; 1790(11): 1441-7.
27. Al-Taie OH, Seufert J, Mork H, et al. A complex DNA-repeat structure within the selenoprotein P promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency. Eur J Hum Genet 2002; 10(9): 499-504.
28. Dreher I, Jakobs TC, Köhrle J. Cloning and characterization of the human selenoprotein P promoter. J Biol Chem 1997; 272(46): 29364-71.
29. Mostert V, Wolff S, Dreher I, et al. Identification of an element within the promoter of human selenoprotein P responsive to transforming growth factor-beta. Eur J Biochem 2001; 268: 6176-81.
30. Zhang J, Wang L, Li G, et al. Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Cancer 2011; 63(5): 778-89.
31. Brigelius-Flohé R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 1999; 27(9-10): 951-65.
32. Bellinger FP, Raman AV, Reeves MA, et al. Regulation and function of selenoproteins in human disease. Biochem J 2009; 422(1): 11-22.
33. Thomas JP, Geiger PG, Maiorino M, et al. Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim Biophys Acta 1990; 1045: 252-60.
34. Brigelius-Flohe R. Glutathione peroxidases and redoxregulated transcription factors. Biol Chem 2006; 387: 1329-35.
35. Zhang N, Jing W, Cheng J, et al. Molecular characterization and NF-kappab-regulated transcription of selenoprotein S from the bama mini-pig. Mol Biol Rep 2011; 38(7): 4281-6.
36. Gao Y, Hannah N, Wanyoni S, et al. Activation of the selenoprotein SEPS1 gene expression by pro-inflammatory cytokines in hepg2 cells. Cytokine 2006; 33: 246-51.
37. Kelly E, Greene CM, Carroll TP, et al. Selenoprotein S/SEPS1 modifies endoplasmic reticulum stress in z variant alpha1- antitrypsin deficiency. J Biol Chem 2009; 284(25): 16891-7.
38. Selenius M, Rundlöf AK, Olm E, et al. Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid Redox Signal 2010; 12(7): 867-80.
39. Shchedrina VA, Zhang Y, Labunskyy VM, et al. Structure-function relations, physiological roles, and evolution of mammalian ERresident selenoproteins. Antioxid Redox Signal 2010; 12(7): 839-49.
40. Hesketh J, Meplan C. Transcriptomics and functional genetic polymorphisms as biomarkers of micronutrient function: Focus on selenium as an exemplar. Proc Nutr Soc 2011; 31-9.
41. Chen J, Cao Q, Qin C, et al. Gpx-1 polymorphism (rs1050450) contributes to tumor susceptibility: Evidence from meta-analysis. J Cancer Res Clin Oncol 2011; 137(10): 1553-61.
42. Tang TS, Prior SL, Li KW, et al. Association between the rs1050450 glutathione peroxidase-1 (c > t) gene variant and peripheral neuropathy in two independent samples of subjects with diabetes mellitus. Nutr Metab Cardiovasc Dis 2012; 22(5): 417-25.
43. Xiong YM, Mo XY, Zou XZ, et al. Association study between polymorphisms in selenoprotein genes and susceptibility to Kashin- Beck disease. Osteoarthritis Cartilage 2010; 18(6): 817-24.
44. Meplan C, Hughes DJ, Pardini B, et al. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010; 31(6): 1074-9.
45. Udler M, Maia A-T, Cebrian A, et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 2007; 25(21): 3015-23.
46. Meplan C, Nicol F, Burtle BT, et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, Se intake, and cancer status. Antioxid Redox Signal 2009; 11(11): 2631-40.
47. Hesketh J. Nutrigenomics and selenium:Gene expression patterns, physiological targets and genetics. Annu Rev Nutr 2008; 28: 157-77.
48. Ferguson LR, Karunasinghe N. Nutrigenetics, nutrigenomics, and selenium. Front Genet 2011; 215.
49. Duffield AJ, Thomson CD, Hill KE, et al. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 1999; 70(5): 896-903.
50. Levander OA. Scientific rationale for the 1989 recommended dietary allowance for selenium. J Am Diet Assoc 1991; 91(12): 1572-6.
51. World Health Organization. Trace Elements in Human Nutrition and Health. Geneva: World Health Organization 1996.
52. Karunasinghe N, Ferguson LR, Tuckey J, et al. Hemolysate thioredoxin reductase and glutathione peroxidase activities correlate with serum selenium in a group of New Zealand men at high prostate cancer risk. J Nutr 2006; 136(8): 2232-5.
53. Xia Y, Hill KE, Li P, et al. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: A placebo-controlled, doubleblind study of selenomethionine supplementation in seleniumdeficient Chinese subjects. Am J Clin Nutr 2010; 92(3): 525-31.
54. Chiang EC, Shen S, Kengeri SS, et al. Defining the optimal selenium dose for prostate cancer risk reduction: Insights from the U-shaped relationship between selenium status, DNA damage, and apoptosis. Dose Response 2009; 8(3): 285-300.
55. Waters DJ, Shen S, Glickman LT, et al. Prostate cancer risk and DNA damage: Translational significance of selenium supplementation in a canine model. Carcinogenesis 2005; 26(7): 1256-62.
56. HapMap: Generic genome browser version. Available from: http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28_B36/ [Accessed July 8, 2012].
57. Wendel A. Glutathione peroxidase. Methods Enzymol 1981; 77: 325-33.
58. Smith AD, Levander OA. High-throughput 96-well microplate assays for determining specific activities of glutathione peroxidase and thioredoxin reductase. Methods Enzymol 2002; 347: 113-21.
59. Collins A, Dusinska M, Franklin M, et al. Comet assay in human biomonitoring studies: Reliability, validation, and applications. Environ Mol Mutagen 1997; 30(2): 139-46.
60. Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STATJACK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 2010; 690(1-2): 108-15.
61. Collins AR, Horvathova E. Oxidative DNA damage, antioxidants and DNA repair: Applications of the Comet assay. Biochem Soc Trans 2001; 29(Pt 2): 337-41.
62. Collins AR, Oscoz AA, Brunborg G, et al. The Comet assay: Topical issues. Mutagenesis 2008; 23(3): 143-51.
63. Rongpu Y, Jiachen H, Gongkan F, et al. Fluorometric determination of micro-amounts of selenium in human blood, using 2,3-diaminonaphthalene. Med Lab Sci 1986; 43(4): 331-4.
64. Watkinson JH. Semi-automated fluorimetric determination of nanogram quantities of selenium in biological materials. Anal Chim Acta 1979; 105: 319-25.
65. Watkinson JH, Brown MW. New phase separating device and other improvements in the semi-automated fluorimetric determination of selenium. Anal Chim Acta 1979; 105: 451-4.
66. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7(10): 781-91.
67. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2011.
68. Jarrett SG, Boulton ME. Consequences of oxidative stress in agerelated macular degeneration. Mol Aspects Med 2012 Apr 9 [Epub ahead of print].
69. Castro Mdel R, Suarez E, Kraiselburd E, et al. Aging increases mitochondrial DNA damage and oxidative stress in liver of rhesus monkeys. Exp Gerontol 2012; 47(1): 29-37.
70. Maurya PK, Kumar P, Siddiqui N, et al. Age-associated changes in erythrocyte glutathione peroxidase activity: Correlation with total antioxidant potential. Indian J Biochem Biophys 2010; 47(5): 319-21.
71. Beckett JM, Ball MJ. Marginal selenium status in Northern Tasmania. Br J Nutr 2011; 106(5): 718-24.
72. Ravn-Haren G, Krath BN, Overvad K, et al. Effect of long-term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolising enzymes in healthy elderly volunteers from the Danish Prevention of Cancer by Intervention by Selenium (PRECISE) Pilot study. Br J Nutr 2008; 99(6): 1190-8.
73. Venkateshappa C, Harish G, Mahadevan A, et al. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: Implications for neurodegeneration in Alzheimer's disease. Neurochem Res 2012; 37(8): 1601-14.
74. Berggren MM, Mangin JF, Gasdaka JR, et al. Effect of selenium on rat thioredoxin reductase activity: Increase by supranutritional selenium and decrease by selenium deficiency. Biochem Pharmacol 1999; 57(2): 187-93.
75. Lin E, Armstrong-Moore D, Liang Z, et al. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity (Silver Spring) 2011; 19(3): 588-94.
76. Shea MK, Booth SL, Gundberg CM, et al. Adulthood obesity is positively associated with adipose tissue concentrations of vitamin k and inversely associated with circulating indicators of vitamin K status in men and women. J Nutr 2010; 140(5): 1029-34.
77. Jacobson GA, Narkowicz C, Tong YC, et al. Plasma glutathione peroxidase by ELISA and relationship to selenium level. Clin Chim Acta 2006; 369(1): 100-3.
78. Fischer JL, Mihelc EM, Pollok KE, et al. Chemotherapeutic selectivity conferred by selenium: A role for p53-dependent DNA repair. Mol Cancer Ther 2007; 6(1): 355-61.
79. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci USA 2002; 99(22): 14548-53.
80. Collins AR. The use of bacterial repair endonucleases in the comet assay. Methods Mol Biol 2011; 691: 137-47.
81. Schrauzer GN. Selenomethionine: A review of its nutritional significance, metabolism and toxicity. J Nutr 2000; 130(7): 1653-6.
82. Seitomer E, Balar B, He D, et al. Analysis of saccharomyces cerevisiae null allele strains identifies a larger role for DNA damage versus oxidative stress pathways in growth inhibition by selenium. Mol Nutr Food Res 2008; 52(11): 1305-15.
83. Zhang S, Rocourt C, Cheng WH. Selenoproteins and the aging brain. Mech Ageing Dev 2010; 131(4): 253-60.
84. Mapelli V, Hillestrom PR, Kapolna E, et al. Metabolic and bioprocess engineering for production of selenized yeast with increased content of seleno-methylselenocysteine. Metab Eng 2011; 13(3): 282-93.
85. Morgan KL, Estevez AO, Mueller CL, et al. The glutaredoxin glrx- 21 functions to prevent selenium-induced oxidative stress in caenorhabditis elegans. Toxicol Sci 2010; 118(2): 530-43.
86. Kosenko EA, Suslikov AV, Venediktova NI, et al. Antioxidant enzymes in erythrocytes from hypertension patients receiving lisinopril monotherapy or combined lisinopril plus simvastatin therapy. Biomed Khim 2011; 57(3): 335-42.
87. Mostert V, Lombeck I, Abel J. A novel method for the purification of selenoprotein P from human plasma. Arch Biochem Biophys 1998; 357(2): 326-30.
88. Maes M, Mihaylova I, Kubera M, et al. Lower whole blood glutathione peroxidase (gpx) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: Another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett 2011; 32(2): 133-40.
89. Rayman M, Thompson A, Warren-Perry M, et al. Impact of selenium on mood and quality of life: A randomized, controlled trial. Biol Psychiatry 2006; 59(2):147-54.
90. Kanazawa T, Chana G, Glatt SJ, et al. The utility of selenbp1 gene expression as a biomarker for major psychotic disorders: Replication in schizophrenia and extension to bipolar disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet 2008; 147B(6): 686-9.
91. Davis CD, Tsuji PA, Milner JA. Selenoproteins and cancer prevention. Annu Rev Nutr 2012; Mar 8 [Epub ahead of print].